Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients

Experimental and Clinical Transplantation

Volumn 12, Issue 2, 2014, Pages 117-122

  Nair, Satheesh ^a   Waters, Bradford ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hepatitis C; Liver transplant; Telaprevir

Indexed keywords

CREATININE; CYCLOSPORIN; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; LIVER GRAFT; MALE; MIDDLE AGED; NEUTROPHIL COUNT; RECURRENT INFECTION; RELAPSE; TACHYCARDIA; THROMBOCYTOPENIA; VIROLOGY; DRUG ADMINISTRATION; DRUG COMBINATION; LIVER TRANSPLANTATION; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84898639696     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2013.0225     Document Type: Article

References (16)

1. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32(4):673-684.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889-896.
3. Organ procurement and transplant network and scientific registry of transplant recipients OPTN/SRTR 2010 annual data report United States Organ Transplantation. Liver. 2011:53-74.
4. Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003;52(2):283-287.
5. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004;10(2):199-207.
6. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virologic response 12 to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46(3):459-465.
7. Carrión JA, Navasa M, García-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132(5):1746-1756.
8. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49(2):274-287.
9. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142(6):1373-1383. e1. doi: 10.1053/j.gastro.2012.02.011.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
11. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428.
12. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54(1):20-27.
13. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11(2):179-185.
14. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
15. Mantry PS, Wu C, Weinstein JS, et al. Early and end of treatment Virologic Response in patients with Hepatitis C genotype 1. Recurrence after Liver Transplant treated with triple therapy using Telaprevir: A Single Center Experience. Hepatology. 2012;56(suppl 4) Abstract No. 12;533.
16. Burton JR, O'Leary JG, Verna EC, et al A multicenter Study of Protease inhibitor-Triple Therapy in HCV infected Liver Transplant Recipients. Report From the CRUSH C group A Single Center Experience. Hepatology. 2012; 56(suppl 4) Abstract No. 211;297.